Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
Science Translational Medicine
|
November 19, 2025
Target antigen-displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastoma
Anna Maria Giudice, Stephanie Matlaga, Sydney L Roth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 30, 2025
D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
Anna Maria Giudice, Stephanie Matlaga, Sydney L Roth, et al.
Journal for Immunotherapy of Cancer
|
September 27, 2022
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors
Jessica B Foster, Crystal Griffin, Jo Lynne Rokita, et al.
Science Advances
|
August 23, 2023
A MYCN-independent mechanism mediating secretome reprogramming and metastasis in <i>MYCN</i>-amplified neuroblastoma
Hai-Feng Zhang, Alberto Delaidelli, Sumreen Javed, et al.
Nature Communications
|
August 20, 2024
CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma
Guillem Pascual-Pasto, Brendan McIntyre, Margaret G Hines, et al.
Cancer Discovery
|
September 15, 2022
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma
Kristopher R Bosse, Anna Maria Giudice, Maria V Lane, et al.
Nature
|
November 8, 2023
Targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
Nature
|
November 4, 2021
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
Cancer Research
|
February 22, 2012
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity
Kristopher R Bosse, Sharon J Diskin, Kristina A Cole, et al.
Cancer Cell
|
September 13, 2017
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma
Kristopher R Bosse, Pichai Raman, Zhongyu Zhu, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
Science Translational Medicine
|
November 19, 2025
Target antigen-displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastoma
Anna Maria Giudice, Stephanie Matlaga, Sydney L Roth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 30, 2025
D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
Anna Maria Giudice, Stephanie Matlaga, Sydney L Roth, et al.
Journal for Immunotherapy of Cancer
|
September 27, 2022
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors
Jessica B Foster, Crystal Griffin, Jo Lynne Rokita, et al.
Science Advances
|
August 23, 2023
A MYCN-independent mechanism mediating secretome reprogramming and metastasis in <i>MYCN</i>-amplified neuroblastoma
Hai-Feng Zhang, Alberto Delaidelli, Sumreen Javed, et al.
Nature Communications
|
August 20, 2024
CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma
Guillem Pascual-Pasto, Brendan McIntyre, Margaret G Hines, et al.
Cancer Discovery
|
September 15, 2022
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma
Kristopher R Bosse, Anna Maria Giudice, Maria V Lane, et al.
Nature
|
November 8, 2023
Targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
Nature
|
November 4, 2021
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
Cancer Research
|
February 22, 2012
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity
Kristopher R Bosse, Sharon J Diskin, Kristina A Cole, et al.
Cancer Cell
|
September 13, 2017
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma
Kristopher R Bosse, Pichai Raman, Zhongyu Zhu, et al.
Page
of 6